Latest filing published 14 Dec 2021 for Avalo Therapeutics, Inc., €1,519.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
James Archie Harrell Jr.: trading record in brief
All filings by James Archie Harrell Jr. on record concern Avalo Therapeutics, Inc., in the capacity of senior executive. Over a trading history stretching from 10 December 2018 to 10 December 2021, the count stands at 8 filings.
On the market, this insider has only ever bought: 8 purchases, €80k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2021 alone, the filings show 2 purchases and no sales.
A typical purchase (the median) is worth €11k. 8 out of 8 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The latest filing, published on 14 December 2021, reports an open-market purchase of €1,519 in Avalo Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to James Archie Harrell Jr.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,093 shares@ US$1.57100.0% of flowCommon StockSEC:0001879785-21-000038:0Canonical exit: 10 Mar 2022 (T+90)
- 7,493 shares@ US$2.28100.0% of flowCommon StockSEC:0001192482-21-000499:0Canonical exit: 8 Sept 2021 (T+90)
2 of 2 declarations
